Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of apatinib plus chemotherapy as adjuvant therapy after R0 resection for lung cancer
ChiCTR1800016449Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in bronchial carcinoma, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: 2-year disease-free survival rate. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1800016449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016449.